A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.
Wednesday, June 19, 2024
Dr. Minal Barve
View abstract via above link.
ASCO Poster for Trial 20-13
Related Abstracts
Discover more abstracts for our trials.